Floatz logo

Fruquintinib

Gastrointestinal Tumours

China Medical University, ChinaSmall moleculeActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

43 Active assets in the Gastrointestinal Tumours cohort.

Asset / SponsorPhaseRating
Capecitabine
China Medical University, China
Phase 3BB
Sorafenib
Sichuan Cancer Hospital and Research Institute
Phase 3BB
Irinotecan
Pfizer
Phase 3BB
FLUOROURACILUM
Janssen Research & Development, LLC
Phase 3BB
Octreotide Pamoate
Federico II University
Phase 2B

View all 50 →

Same molecule, other indications

Fruquintinib is also rated in:

metastasis from malignant tumor of colonDormant
BBB
Indicative ·
72 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
67 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →